StockNews.com Initiates Coverage on DBV Technologies (NASDAQ:DBVT)

by · The Cerbat Gem

Analysts at StockNews.com started coverage on shares of DBV Technologies (NASDAQ:DBVT – Get Free Report) in a research note issued to investors on Tuesday. The firm set a “hold” rating on the stock.

A number of other equities research analysts also recently weighed in on the stock. JMP Securities reiterated a “market outperform” rating and set a $10.00 price target on shares of DBV Technologies in a research note on Tuesday, December 10th. HC Wainwright increased their target price on DBV Technologies from $25.00 to $35.00 and gave the stock a “buy” rating in a report on Thursday, October 24th.

Get Our Latest Report on DBVT

DBV Technologies Trading Down 7.9 %

NASDAQ DBVT opened at $3.04 on Tuesday. The company has a fifty day simple moving average of $3.41 and a 200 day simple moving average of $3.95. The company has a market cap of $62.53 million, a P/E ratio of -0.68 and a beta of 0.64. DBV Technologies has a 1 year low of $2.20 and a 1 year high of $10.70.

About DBV Technologies

(Get Free Report)

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.

See Also